SCHEMBL5268491

SCHEMBL5268491

Cc1ccc(C)c(CNC(C)c2c(Cl)cccc2Cl)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CASR P41180 1/20 0.42
RAB9A P51151 2/20 0.39
NPC1 O15118 1/20 0.39
KDM4E B2RXH2 2/20 0.38
ALDH1A1 P00352 2/20 0.38
PTGS2 P35354 4/20 0.38
TAAR1 Q96RJ0 1/20 0.37
LMNA P02545 2/20 0.36
ALOX12 P18054 1/20 0.36
PTGS1 P23219 2/20 0.36
SMN1; SMN2 Q16637 1/20 0.35
MAPT P10636 2/20 0.35
GAA P10253 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
VDR P11473 2/20 0.34
ABCB11 O95342 1/20 0.34
PPARG P37231 1/20 0.34
NR1I3 Q14994 1/20 0.34
KDM4C Q9H3R0 1/20 0.33
HSD17B10 Q99714 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5272102 0.90 ALDH1A1 (0.39) CASRRAB9ANPC1KDM4EALDH1A1
SCHEMBL5270312 0.85 CYP1A2 (0.41) CASRRAB9ANPC1KDM4EALDH1A1
SCHEMBL5272934 0.84 CASR (0.41) CASRRAB9ANPC1KDM4EALDH1A1
SCHEMBL5267954 0.79 RAPGEF4 (0.40) CASRRAB9AALDH1A1PTGS2LMNA
SCHEMBL5270845 0.78 SMN1; SMN2 (0.57) CASRLMNASMN1; SMN2VDR
SCHEMBL5268202 0.77 TAAR1 (0.38) CASRRAB9ANPC1KDM4EALDH1A1
SCHEMBL5272096 0.77 ALDH1A1 (0.39) RAB9ANPC1KDM4EALDH1A1TAAR1
SCHEMBL5268227 0.77 TP53 (0.41) RAB9AKDM4EALDH1A1LMNA
SCHEMBL5267478 0.75 ALDH1A1 (0.45) RAB9ANPC1KDM4EALDH1A1TAAR1
SCHEMBL7198278 0.73 NPC1 (0.39) RAB9ANPC1PTGS2TAAR1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1074539-B1 Process for producing optically active 3,3,3,-trifluoro-2-hydroxy-2-methylpropionic acid, and salt thereof SUMITOMO CHEMICAL CO (JP) 2007-10-17 EP disclosed
US-6894190-B2 Process for producing optically active 3,3,3-trifluoro-2-hydroxy-2-methylpropionic acid, and salt thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2005-05-17 US disclosed
US-20030232886-A1 Process for producing optically active 3,3,3-trifluoro-2-hydroxy-2-methylpropionic acid, and salt thereof SUMITOMO CHEMICAL COMPANY, LIMITED 2003-12-18 US disclosed
US-6653507-B2 Useful intermediate compound of pharmaceuticals for urinary incontinence SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2003-11-25 US disclosed
US-20020143212-A1 Process for producing optically active 3,3,3-trifluoro-2-hydroxy-2-methylpropionic acid, and salt thereof SUMITOMO CHEMICAL COMPANY, LIMITED 2002-10-03 US disclosed
US-6403832-B1 MIXING ACID WITH AMINE, PRECIPITATING SALT, AND FILTERING; GOOD OPTICAL PURITY SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2002-06-11 US disclosed
EP-1074539-A2 Process for producing optically active 3,3,3,-trifluoro-2-hydroxy-2-methylpropionic acid, and salt thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2001-02-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030232886-A1 Process for producing optically active 3,3,3-trifluoro-2-hydroxy-2-methylpropionic acid, and salt thereof ALDH1A2, CYP8B1, CYP11B2 CASR 2902/4885RAB9A 486/4885NPC1 2463/4885
US-20020143212-A1 Process for producing optically active 3,3,3-trifluoro-2-hydroxy-2-methylpropionic acid, and salt thereof ALDH1A2, ALDH7A1, ALDH18A1 CASR 3465/4885RAB9A 523/4885NPC1 2583/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.